Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. Buhelt S, Hansen M B, Søndergaard H B, El Mahdaoui S, Hansen M M, Mahler M R, Romme Christensen J, Sellebjerg F Front Immunol. 2026; 17:1817671. PMID: 42327769. Abstract CommentRecommendBookmarkWatch
